OraSure Technologies Inc (OSUR)

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued UnderperformanceMarch 17, 2026 9:15 AM
Business Wire
Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board


Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the “Board”) outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/
In the letter, Altai calls on the OraSure Board to reach a fair settlement that results in the appointment of Altai’s highly-qualified director nominees, Rishi Bajaj and John Bertrand, to the Board.


Highlights of the letter, which can be found in full here, include:



Chronic Underperformance. OraSure’s share price has dramatically underperformed comparable companies and broader indices over both five- and ten-year periods. Recent underperformance has been driven by repeated operational and strategic failures under the current management team—failures that occurred on the Board’s watch. Despite this track record, the Company continues to burn cash pursuing speculative diagnostics investments to the detriment of shareholders.




A Board Without Skin in the Game. Independent directors collectively own less than 1% of shares outstanding yet collect over $250,000 each per year in compensation. They bear little financial risk for decisions that have destroyed shareholder value. Shareholders who face the very real risk of losing money on their investment deserve a larger voice on the Board.




Pay Without Performance. Over 90% of CEO Carrie Eglinton Manner’s compensation is not tied to share price performance. She has earned an estimated $15 million over her tenure while shareholders have lost 60% of their investment since 2023. Her incentives are plainly misaligned with shareholder interests.




The Imperative for a Strategic Review. OraSure must evaluate a sale of the entire business alongside its current plan. We will represent and advocate for all shareholder interests in this process upon our appointment to the Board to ensure that the outcome delivers the best possible returns to shareholders.




Nominees With a Track Record of Results. Rishi Bajaj led ContextLogic’s transformation from a company burning $80 million of cash per quarter to one that completed a $907.5 million acquisition, producing a share price increase of over 120%. John Bertrand built the company behind the first FDA-cleared autonomous AI diagnostic solution in healthcare. Both nominees will seek to align their compensation directly with shareholder returns.



As previously announced, Altai has formally nominated Rishi Bajaj and John Bertrand for election at the 2026 Annual Meeting of Shareholders.


About Altai Capital Management

Altai Capital Management is a technology-focused investment firm founded in 2009 by Rishi Bajaj. Altai Capital makes long-term investments across a diverse range of financial instruments, including debt, private equity, venture capital, and publicly traded securities. To learn more, visit www.altai.com


Disclaimers

This press release and the opinions herein are for general information only, and are not intended to be, nor should they be construed as, an offer to sell or a solicitation of an offer to buy any security, a recommendation to purchase or sell any security, or legal, financial, tax, investment, or other advice.


Altai Capital Management, L.P., Altai Capital Management, LLC, Altai Capital Osprey, LLC, Rishi Bajaj and John Bertrand (collectively, the “Participants”) intend to file with the SEC a definitive proxy statement and accompanying form of proxy to be used in connection with the solicitation of proxies from the stockholders of OraSure Technologies, Inc. Stockholders are advised to read the definitive proxy statement and other documents related to the solicitation of proxies by the Participants when they become available, as they will contain important information, including additional information related to the Participants. The definitive proxy statement and an accompanying proxy card will be furnished to OraSure Technologies, Inc. stockholders and will be, along with other relevant documents, available at no charge on the SEC website at http://www.sec.gov/.


Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained in Exhibit 1 to the Schedule 14A filed by the Participants with the SEC on March 17, 2026. This document is available free of charge from the source indicated above.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260317768148/en/
Media Contact:

ASC Advisors

Taylor Ingraham / Max Rayden

tingraham@ascadvisors.com / mrayden@ascadvisors.com


Original: Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

OSUR under $5

Wow. Clay Trader sure blew that call on 10/19/20.

Going forward... Zacks has OSUR on it's "Buy" list for stocks under 10 bucks. That's a good sign.

Industry’s First FDA Authorization

Unique, POS now. Imho

OraSure’s Oragene®•Dx Saliva Collection Kit Included in Industry’s First FDA Authorization for a Whole Exome Sequencin...

Read the news here

$$$ GLTA $$$

* * $OSUR Video Chart 10-19-2020 * *

Link to Video - click here to watch the technical chart video

JUST IN: $OSUR Why OraSure Technologies Stock Is Soaring Today

Shares of OraSure Technologies (NASDAQ: OSUR) were soaring 15.2% as of 11:09 a.m. EDT on Monday. The big jump came after the company announced that the Food and Drug Administration granted Emergency Use Authorization (EUA) for the OMNIgene ORAL saliva collection and stabilization de...

Got this from OSUR - Why OraSure Technologies Stock Is Soaring Today

Just In: $OSUR OraSure's OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2

BETHLEHEM, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its DNA Genotek subsidiary has received Emergency Use Auth...

Read the whole news OSUR - OraSure's OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2

https://www.globenewswire.com/news-release/2020/10/19/2110238/0/en/OraSure-s-OMNIgene-ORAL-Collection-Device-Receives-FDA-Emergency-Use-Authorization-for-SARS-CoV-2.html

OSUR $$$

Saw this on CBS news last night for rapid saliva test covid players

OSUR $$$

$OSUR | #Orasure Tech Reversal Trade




The stock has retraced and bounced perfectly of the Fibonacci Golden pockets once again.
Fridays seen increased volume and bullish price action.
50 & 100 Moving Averages support once again
Alert set for break above $15.25 for long into huge gap.
Stochastic and RS bottomed and reversing.
Speculative and high risk
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.

UBS Virtual Global Healthcare Conference

Looks like good things ahead, recording can be accessed below

https://event.webcasts.com/starthere.jsp?ei=1309729&tp_key=b56dfb64ac

Stockholder meeting was pretty uneventful.

Looking forward to the stockholder meeting (video) on the 19th. I'm set!

More nice news this AM. This biotech is turning in to a beast. In since $11 area and dollar costing the whole way up for long term portfolio.

OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries
May 12 2020 - 08:00AM GlobeNewswire Inc.

OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service.
The unified Diversigen operation will continue to offer the science-driven, customized solutions for metagenomics sequencing, bioinformatics, and statistical analysis for the study of the microbiome for which CoreBiome and Diversigen are known. The unification elevates Diversigen as the cornerstone brand for microbiome services in the industry.

The combined organization includes scientific experts representing more than a century of microbiome experience and over 300 articles in respected scientific publications with more than 100,000 citations.

“The new Diversigen brand reflects the combined strength and innovation of these two microbiome service pioneers and positions the OraSure family of companies as an industry leader in this fast-growing industry. Together they will enable us to expand our services as we work to advance global health and bring our customers the tools, services and data-driven insights they need to get reliable, actionable answers to their most critical scientific and healthcare questions,” said Stephen S. Tang, Ph.D., President and Chief Executive Officer, OraSure Technologies, Inc.

All services previously offered under the CoreBiome brand will continue to be available from Diversigen, offering the microbiome market unparalleled choice in sequencing, bioinformatics and analysis services.

The rebrand was implemented after in-depth research, market analysis, and customer conversations. A new Diversigen logo will bring a sharp new visual identity, representing the best of both CoreBiome and Diversigen and characterizes the brand as smart, market-driven, and innovative.

The new Diversigen website is available at diversigen.com.

Mid 18's up pre-market. Easily 20's this week.

Possible 1 billion kits produced in 2021 and the company only valued at $1 billion. This is going a ton higher as it has been.

Article today, big things ahead for Orasure. 2021, possibly billions of units, that’s huge revenues..

OraSure President and CEO Stephen Tang said the company began considering developing a test as COVID-19 began spreading in January and February.

The company plans to develop a SARS-CoV-2 that, like its HIV test, will be suitable for home use and can provide results in under an hour, Tang said. He said the company aims to launch the product in September. Tang said that OraSure can currently manufacture about 13 million tests per year.

He noted, however, that some official plans to safely reopen the economy call for a billion tests per year.

"We're going to have to find a way to massively scale up," he said. "We're looking to design massive manufacturing of this from the start. Our job is to find facilities and manufacturers and partners who can jump in quickly to that manufacturing environment."

He said he anticipated being able to reach "full-scale manufacturing sometime in 2021," with a target of "tens of millions to a billion units per year."

https://www.modernhealthcare.com/technology/rapid-antigen-assays-could-prove-key-addressing-sars-cov-2-testing-limitations

This clearly is trading like a buyout is coming imo...

Nice end of day buying, heading for $20+ next week imo. Great months ahead.

https://www.globenewswire.com/news-release/2020/05/06/2028785/0/en/OraSure-Announces-2020-First-Quarter-Financial-Results-and-Provides-COVID-19-Update.html

strong day here ... OSUR

52 week high again, $20's coming.

Earnings and conference call tomorrow. News today was pretty good too.

putting in a solid base here chart wise ... OSUR

A daily double here. Their part of Biocerna’s FDA nasal test and are creating a saliva test at home kit as well. $$ flowing in here. Looking forward to call this week.

Nice update! Big week ahead.

DNA Genotek Inc., a leading provider of sample collection kits and end-to-end services and a wholly-owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), announced today that its ORAcollect®·RNA kit (OR-100) was included as the collection device for anterior nares (nasal) samples under a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to Biocerna LLC for its PCR-based SARS-CoV-2 assay.

https://www.streetinsider.com/dr/news.php?id=16824757&gfv=1

Conference call Wednesday and I’m sure an update this week on the rapid home CV saliva testing kits. My guess we will be over $20 by Friday.

Beast...eom

Nice day again today, back over $16 tomorrow imo.

$16 will be cheap, by mid May this will be well in to the $20s, add in an approval for home test kits easily in the $30s.


https://www.inquirer.com/business/phillydeals/coronavirus-tang-orasure-saliva-testing-fda-20200418.html

First post, it is quiet here. Got excited when I read about them, but entered a little high ($16) Hopefully patience will be rewarded.

thanks ... I will slowly accumulate on any dips now. Love this share structure

OraSure Technologies, Inc.

Shares Outstanding
62,748,100

Float
62,133,357

Insider Ownership
1.30%

Insitutional Ownership
95.70%

Good to see you here, as you can see is trending higher. They will be a few billion dollar market cap company by the end of the summer.

Looks like another nice find HH. I hate to chase but did get a starter pre-market here

Been alone here for weeks, happy as a peach. Entry at $11.23 on the mother lode company of the home self CV test kits still has a long way to go. Hasn’t even been announced yet. $20s here next week.

Saliva testing mentioned on MSNBC tonight as the only way to get the country opened up again the right way. Trump mentioned there’s a game changing test about to be announced in a few weeks, OSUR continues to make new highs daily and has the at home saliva test to get it done. Should be an interesting few weeks here going forward if there’s any connection.

Back to $20s+ coming. Great weekend article..

U.S. grant speeds this Pa. coronavirus test to market this year
Updated: April 18, 2020 - 5:21 AM

https://www.inquirer.com/business/phillydeals/coronavirus-tang-orasure-saliva-testing-fda-20200418.html

This will be a huge hit, rapid in-home testing, which will ease the burden on lab-based testing and folks don’t have to leave the house for test and results.

Company continues to make new highs daily. Still more good news on the way.

An in-home coronavirus test is being developed in Bethlehem. And the feds are backing it.

Updated Apr 06, 2020; Posted Apr 06, 2020

OraSure Technologies, the Bethlehem-based tech company that gained notoriety years ago with its rapid HIV test, has been awarded a $710,310 federal contract to develop an in-home coronavirus test, the company announced Monday morning.

The contract comes from the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services. It will enable OrasSure to file for special authorization from the FDA allowing the in-home test to debut in the U.S. market.

OraSure is billing the test’s development as a possible breakthrough in the fight against the coronavirus pandemic.

Once its developed and the necessary approvals are obtained, the test would help alleviate the pressure on over-burdened healthcare systems, a news release from OraSure says.

“Healthcare providers, retailers, and online vendors could ship tests directly to an individual’s home, eliminating unnecessary trips to hospitals, doctors’ offices, and testing facilities,” the release says. “This would help maintain social distancing and curb the spread of coronavirus through symptomatic and asymptomatic transmission. Rapid in-home testing could also ease the burden on lab-based testing.”

Ticker keeps hitting new highs and is in the rapid testing via saliva CV-19 testing. Looks like a winner from here imo. FDA approval for in-home test news any day now imo.

-The diagnostic test company said it plans to file for FDA Emergency Use Authorization allowing for an in-home self-test to debut into the U.S. market.

-OraSure said its portable rapid test platform uses an oral fluid sample and provides results in 20 minutes, with no instrumentation or trained personnel needed to administer the test or read the results.

-Co announced it has been awarded a $710,310 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), to develop a pan-SARS-coronavirus antigen rapid in-home self-test that uses oral fluid samples. This support from BARDA will enable OraSure to file for FDA Emergency Use Authorization (EUA) allowing for an in-home self-test to debut into the U.S. market.

Security OSUR / OraSure Technologies, Inc. (68554V108)
President and CEO TANG STEPHEN S PHD
ISIN US68554V1089
Industry Surgical and Medical Instruments and Apparatus
Institutional Owners 401
Institutional Shares 58,419,785 - 94.70%
Common Shares Outstanding 61,687,392 shares (as of 2019-03-31)
Institutional Value $ 1,736,356 USD


https://fintel.io/so/us/osur

Hellooo... anyone home?

Followed at 6.
In at 8.
Up to 10. Held
Down to 6 again.
Up to 10 again out.


Seemspromising.
Osur

Just started to follow OSUR

Triggers gave been hit.

More gravey
Over due.

why the drop today?

20.00 boom

Boom holy cow